PBS Archives - Insight Presented by Prime Creative Media Mon, 02 May 2022 06:11:53 +0000 en-US hourly 1 https://www.insightnews.com.au/wp-content/uploads/2024/02/cropped-Insight-favicon-32x32.png PBS Archives - Insight 32 32 Federal election: PBS script savings regardless of who’s elected https://www.insightnews.com.au/federal-election-pbs-script-savings-regardless-of-whos-elected/ Mon, 02 May 2022 00:17:50 +0000 https://www.insightnews.com.au/?p=27002
The maximum co-payment would be reduced to $30 under Labor, and $32.50 under the Coalition.

Both sides of the political divide are promising to slash the maximum price Australians pay for a PBS script, if elected to govern at the 21 May election, in a move set to benefit thousands of patientsRead More

The post Federal election: PBS script savings regardless of who’s elected appeared first on Insight.

]]>
The maximum co-payment would be reduced to $30 under Labor, and $32.50 under the Coalition.
Both sides of the political divide are promising to slash the maximum price Australians pay for a PBS script, if elected to govern at the 21 May election, in a move set to benefit thousands of patients
Read More

The post Federal election: PBS script savings regardless of who’s elected appeared first on Insight.

]]> What’s in the 2022-23 Federal Budget for the eye health sector? https://www.insightnews.com.au/whats-in-the-2022-23-federal-budget-for-the-eye-health-sector/ Thu, 31 Mar 2022 21:38:09 +0000 https://www.insightnews.com.au/?p=26461 Federal Budget
The 2022 federal election must be held before 21 May.

The post What’s in the 2022-23 Federal Budget for the eye health sector? appeared first on Insight.

]]> Federal Budget
The 2022 federal election must be held before 21 May.
The Federal Government has laid out a $132 billion health agenda for the coming year – if it regains power at the next election – and while there were no major wins for eye health, changes to the PBS
Read More

The post What’s in the 2022-23 Federal Budget for the eye health sector? appeared first on Insight.

]]> Beovu AMD therapy now listed on the PBS https://www.insightnews.com.au/beovu-amd-therapy-now-listed-on-the-pbs/ Mon, 04 Oct 2021 01:00:05 +0000 https://www.insightnews.com.au/?p=22971
The American Medical Association’s United States Adopted Names (USAN) Council, with the WHO, approved the name.

The post Beovu AMD therapy now listed on the PBS appeared first on Insight.

]]>
The American Medical Association’s United States Adopted Names (USAN) Council, with the WHO, approved the name.
Almost 13,000 Australians could save thousands annually with the Pharmaceutical Benefits Scheme (PBS) listing of Beovu (brolucizumab) for neovascular age-related macular degeneration (nAMD) from this month,
Read More

The post Beovu AMD therapy now listed on the PBS appeared first on Insight.

]]> Novartis secures PBS recommendation for Beovu https://www.insightnews.com.au/novartis-secures-pbs-recommendation-for-beovu/ Mon, 26 Apr 2021 22:44:37 +0000 http://www.insightnews.com.au/?p=20000 Novartis ophthalmology sale
The Novartis ophthalmology unit could fetch US$5 billion (AU$7.5 billion).

The post Novartis secures PBS recommendation for Beovu appeared first on Insight.

]]> Novartis ophthalmology sale
The Novartis ophthalmology unit could fetch US$5 billion (AU$7.5 billion).
An independent expert panel has recommended Novartis’ treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD) patients
Read More

The post Novartis secures PBS recommendation for Beovu appeared first on Insight.

]]> Anti-VEGF becomes most expensive drug on PBS https://www.insightnews.com.au/anti-vegf-becomes-most-expensive-drug-on-pbs/ Tue, 16 Feb 2021 20:26:53 +0000 http://www.insightnews.com.au/?p=18870
The approval is based on the 48-week results of PULSAR and PHOTON trials.

The post Anti-VEGF becomes most expensive drug on PBS appeared first on Insight.

]]>
The approval is based on the 48-week results of PULSAR and PHOTON trials.
The Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a hepatitis C drug to become the costliest subsidised drug for
Read More

The post Anti-VEGF becomes most expensive drug on PBS appeared first on Insight.

]]> Brand names banished under new prescribing regulations https://www.insightnews.com.au/brand-names-banished-under-new-prescribing-regulations/ Thu, 28 Jan 2021 22:14:05 +0000 http://www.insightnews.com.au/?p=18722
Four cases of enucleation and four deaths are alleged to have occurred from the contaminated drops.

The post Brand names banished under new prescribing regulations appeared first on Insight.

]]>
Four cases of enucleation and four deaths are alleged to have occurred from the contaminated drops.
New regulations come into force from 1 February requiring doctors to prescribe PBS drugs by their active ingredient instead of their brand name, in a bid to encourage greater uptake of generic medicines
Read More

The post Brand names banished under new prescribing regulations appeared first on Insight.

]]> Clinical trial results reinforce potential new treatment for DME https://www.insightnews.com.au/clinical-trial-results-reinforce-potential-new-treatment-for-dme/ Thu, 17 Dec 2020 01:11:54 +0000 http://www.insightnews.com.au/?p=18461
Novartis is working with regulatory authorities to bring Beovu to DME patients.

The post Clinical trial results reinforce potential new treatment for DME appeared first on Insight.

]]>
Novartis is working with regulatory authorities to bring Beovu to DME patients.
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to treat diabetic macular edema (DME). KESTREL is the second pivotal Phase
Read More

The post Clinical trial results reinforce potential new treatment for DME appeared first on Insight.

]]> Dry eye treatment in Australia https://www.insightnews.com.au/dry-eye-treatment-in-australia/ Mon, 10 Aug 2020 23:16:53 +0000 http://www.insightnews.com.au/?p=16023
Dr Brendan Cronin is a corneal surgeon and director of education at the Queensland Eye Institute.

The post Dry eye treatment in Australia appeared first on Insight.

]]>
Dr Brendan Cronin is a corneal surgeon and director of education at the Queensland Eye Institute.
Dry eye remains a very common presentation to primary eyecare practitioners in Australia. Many experienced practitioners feel that the incidence of dry eye is increasing significantly. This is a complex
Read More

The post Dry eye treatment in Australia appeared first on Insight.

]]> Anti-inflammatory eye drops added to PBS for Indigenous patients https://www.insightnews.com.au/anti-inflammatory-eye-drops-added-to-pbs-for-indigenous-patients/ Wed, 04 Mar 2020 21:54:56 +0000 http://www.insightnews.com.au/?p=13723

The post Anti-inflammatory eye drops added to PBS for Indigenous patients appeared first on Insight.

]]>
Prednefrin Forte eye drops can now be prescribed to Aboriginal and Torres Strait Islander patients under the Pharmaceutical Benefits Scheme (PBS) for certain cases of severe eye inflammation. The National
Read More

The post Anti-inflammatory eye drops added to PBS for Indigenous patients appeared first on Insight.

]]> Jetrea eye injection receives new PBS listing https://www.insightnews.com.au/jetrea-eye-injection-receives-new-pbs-listing/ Tue, 08 Oct 2019 23:51:05 +0000 http://www.insightnews.com.au/?p=10459

The post Jetrea eye injection receives new PBS listing appeared first on Insight.

]]>
A new formulation of the Jetrea intravitreal injection has been listed on Pharmaceutical Benefits Scheme (PBS), replacing the current powder form of the drug. Jetrea Ready-To-Use (RTU), a pre-diluted formulation
Read More

The post Jetrea eye injection receives new PBS listing appeared first on Insight.

]]>